1994 Volume 42 Issue Supplement4 Pages 405-417
Biapenem (BIPM) is a new carbapenem antibiotic, which characterized by its wide spectrum and chemical stability against dehydropeptidase-I. We performed laboratory and clinical studies on the drug to evaluate its usefulness in respiratory tract infection.
MIC50 and MIC90 of BIPM at 106 CFU/ml were 0.78 and 3.13 μg/ml against Haemophilus influenzae (42 strains), 0.05 and 0.01μg/ml againstS. pneumoniae (45 strains), 0.1 and 0.1μg/ml against B. catarrhalis (42 strains), 0.1 and 50μg/ml against S. aureus (53 strains), and 0.1 and 25μg/ml against P. aeruginosa (50 strains), respectively.
The peak sputum levels of BIPM ranged 0.26 to 0.76μg/ml in four patients and the ratios of peak sputum levels to peak serum levels were 2.18 to 6.05% in the same patients.
Nineteen patients with respiratory infections were administrated BIPM and the results were four cases were excellent and all the others were good. Only one patients (case 5) developed mild diarrhea but he could continue taking the drugs.
Causative organisms were S. pneumoniae (6 strains), P. aeruginosa (6), H. influenzae (4), B. catarrhalis (2) and S. aureus (1). All strains were eradicated except one strain of P. aeruginosa which was reduced in number after BIPM administration.
The bacteriological effect was 94.7% and the clinical efficacy was 100%.
From these results, we could conclude that BIPM was a very effective new carbapenem antibiotic for the treatment of respiratory infections with high safety.
